Assessment of T-cell based immunotherapy targeting EGFR with immune-molecular targeted combination therapy for treatment of reflactory cancer.
| Project/Area Number |
25460430
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Asahikawa Medical College |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 腫瘍免疫 |
|---|
| Outline of Final Research Achievements |
We evaluated the capacity of predicted CD4 T-cell peptide epitopes from HER family to induce anti-tumor immune responses. Among several predicted peptide epitopes, EGFR875-889 elicited CD4 T cell responses that were restricted by several HLA-DR alleles, indicating that the peptide functions as a promiscuous T cell epitope. The CD4 T cells were capable of directly recognized and killed HNSCC or lymphoma cells expressing antigens. Finally, we examined whether an EGFR tyrosine kinase inhibitor would affect CD4 T cell tumor reactivity. Treatment of tumor cells with the EGFR inhibitors enhanced tumor recognition by EGFR875-889 reactive T cells presumably due to the up-regulation of HLA-DR expression in the tumor cells. The results demonstrate the utility of EGFR inhibitors as immune modulators. These observations may facilitate the translation of T-cell based immunotherapy into the clinic for the treatment of maligancies and rational explanation for immune-targeted combination therapy.
|
Report
(4 results)
Research Products
(16 results)
-
-
-
-
-
-
[Journal Article] Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53.2014
Author(s)
Kumai T, Ishibashi K, Oikawa K, Matsuda Y, Aoki N, Kimura S, Hayashi S, Kitada M, Harabuchi Y, Celis E, Kobayashi H.
-
Journal Title
Cancer Immunol Immunother
Volume: in press
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
